Literature DB >> 6202686

Inhibition of human activated Factor X by antithrombin III and alpha 1-proteinase inhibitor in human plasma.

S N Gitel, V M Medina, S Wessler.   

Abstract

The inhibition of activated human Factor X by human plasma protease inhibitors was investigated in both purified and plasma systems. In the former, antithrombin III, alpha 1-proteinase inhibitor, and alpha 2-macroglobulin, at normal plasma concentrations, markedly inhibited activated Factor X. Significant inhibition by alpha 2-antiplasmin, however, was only achieved when present at 40 times its plasma concentration. The relative rates of inhibition of activated Factor X coagulant activity in normal human plasma, antithrombin III-deficient plasma, and alpha 1-proteinase inhibitor-deficient plasma were 1.0, 0.63, and 0.75, respectively. From these relative rates of inhibition and their measured concentrations in the 3 plasmas, it was calculated that antithrombin III, alpha 1-proteinase inhibitor, and alpha 2-macroglobulin contribute 53, 35, and 12%, respectively, to the inhibition of activated Factor X in normal human plasma. Using 125I-labeled activated Factor X and a combination of sodium dodecyl sulfate disc gel electrophoresis and immunoadsorption, it was then demonstrated that antithrombin III accounted for 45-55%, alpha 1-proteinase inhibitor, 35-40%, and alpha 2-macroglobulin, 10-15% of the inhibition of the labeled protease in normal human plasma. The values obtained with the deficient plasmas are consistent with the distribution of activated Factor X-inhibitor complexes in normal human plasma. These data show by two independent techniques, one measuring coagulant activity and the other 125I-labeled activated Factor X-inhibitor complexes, that both antithrombin III and alpha 1-proteinase inhibitor are the major inhibitors of activated Factor X in normal human plasma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6202686

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  A rapid pro-hemostatic approach to overcome direct oral anticoagulants.

Authors:  Nabil K Thalji; Lacramioara Ivanciu; Robert Davidson; Phyllis A Gimotty; Sriram Krishnaswamy; Rodney M Camire
Journal:  Nat Med       Date:  2016-07-25       Impact factor: 53.440

2.  Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro.

Authors:  Matthew W Bunce; Raffaella Toso; Rodney M Camire
Journal:  Blood       Date:  2010-09-23       Impact factor: 22.113

3.  Elevated factor Xa activity in the blood of asymptomatic patients with congenital antithrombin deficiency.

Authors:  K A Bauer; T L Goodman; B L Kass; R D Rosenberg
Journal:  J Clin Invest       Date:  1985-08       Impact factor: 14.808

4.  The nature of the stable blood clot procoagulant activities.

Authors:  Thomas Orfeo; Kathleen E Brummel-Ziedins; Matthew Gissel; Saulius Butenas; Kenneth G Mann
Journal:  J Biol Chem       Date:  2008-02-11       Impact factor: 5.157

5.  A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.

Authors:  Lacramioara Ivanciu; Raffaella Toso; Paris Margaritis; Giulia Pavani; Haein Kim; Alexander Schlachterman; Jian-Hua Liu; Valerie Clerin; Debra D Pittman; Rosalind Rose-Miranda; Kathleen M Shields; David V Erbe; James F Tobin; Valder R Arruda; Rodney M Camire
Journal:  Nat Biotechnol       Date:  2011-10-23       Impact factor: 54.908

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.